0 items | $0.00

C5b-9, Rat, mAb 2A1, immuno assay antibody

Catalog #: HM3033-IA

Quantity: 0.5 mg

Availability: In stock

Description: C5b-9, Rat, mAb 2A1, immuno assay antibody

The monoclonal antibody 2A1 recognizes rat C5b-9. The antibody was shown to compete with antibodies to human C9 for its binding site on the C5b-9 complex, indicating that the reactive epitope is located on the C9 molecule. C5b-9 membrane attack complexes are assembled from five precursor molecules in the serum. Proteolytic cleavage of C5 by C5 convertase generates C5b which initiates assembly of the C5b-9 complex. The last step of C5b-9 complex formation involves polymerization of C9 which accompanies insertion of the complex into the cell membrane. During formation of C5b-8 and C9 polymerization, neoantigens are generated which are unique to the C5b-9 complex and are not present on any of the individual native complex components. The complement regulatory proteins CD59 and complement S-protein can both prevent C5b-9 insertion into the cell membrane. The formed SC5b-9 complex is unable to attach to cells and is cytolytically inactive.C5b-9 is involved in the progression of chronic proteinuric renal disease by mediating continuous tubulointerstitial damage. Early tubulointerstitial injury in the remnant kidney can be improved when C5b-9 complex forming is abrogated.
The monoclonal antibody 2A1 was raised against a rat C5b-9 neoantigen. Monoclonal antibody 2A1 can be used as a coating antibody to detect C5b-9 in plasma and urine samples.


Catalog number HM3033-IA
Product type Monoclonal antibodies
Quantity 0.5 mg
Formulation 0.5 mg of 0.2 μm filtered protein G purified antibody solution in PBS (exact concentration is indicated on the label).
Application F, FC, IA, IF, P, W
Application Notes IA: plates were coated with 30μg/ml in 50mM carbonatebuffer, pH10.6 for 16h at 4°C.(Ref.1)
W: A non-reduced sample treatment and SDS-Page was used. The band size is >200 kDa (Ref.1).
IHC-P: Tissue sections fixed in formalin were pretreated with protease type XXIV for 10 minutes at 37⁰C before incubation (Ref.6).
IHC-F: Tissue sections were fixed in acetone for 10 minutes at room temperature before incubation (Ref. 3).
Use Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.
Immunogen Rat C5b-9
Isotype Mouse IgG1
Species Rat
Alias Membrane attack complex, MAC, TCC, Terminal Complement Complex
Positive Control Glomeruli of rats treated with anti-Thy-1.1 antibodies
References 1. Schulze, M et al. Increased urinary excretion of C5b-9 distinguishes passive Heymann nephritis in the rat. Kidney Int. 1989, 35: 60
2. Brandt, J et al. Role of the complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis. Kidney Int. 1996, 49: 335
3. Sato, T et al.The terminal sequence of complement plays an essential role in antibody-mediated renal cell apoptosis. J Am Soc Nephrol 1999, 10: 1242
4. Duijvestijn, A. Complement activation by anti-endothelial cell antibodies in MHC-mismatched and MHC-matched heart allograft rejection: anti-MHC, but not anti non-MHC alloantibodies are effective in complement activation. Transpl. Int. 2000, 13:363
5. Yamada,K et al. Clusterin is up-regulated in glomerular mesangial cells in complement-mediated injury. Kidney Intern 2001. 59:137
6. Nangaku M et al. C6 mediates chronic progression of tubulointerstitial damage in rats with remnant kidneys J. Am. Soc. Nephrol. 2002, 13: 928
7. Rangan GK et al. C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis. Kidney Int 2004, 66: 1838
8. Ostendorf, T et al. Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 2006, 17: 1054
9. Pol, P; Pathogenic role of complement in renal ischemia/reperfusion injury. Thesis 2013
10. Kotimaa, J et al; Functional assessment of rat complement pathway activities and quantification of soluble C5b-9 in an experimental model of renal ischemia/reperfusion injury. J Imm Meth 2014, 412: 14
Storage and stability Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
Precautions For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Disease Infectious diseases, Nephrology